| Literature DB >> 27881094 |
Kedan Cai1, Qun Luo2, Beixia Zhu1, Lina Han1, Dan Wu1, Zhiwei Dai1, Kaiyue Wang1.
Abstract
BACKGROUND: Patients with peritoneal dialysis are in the persistent inflammation state and have elevated arterial stiffness. Neutrophil-lymphocyte ratio(NLR) is a new inflammatory marker in renal and cardiac disorders. Brachial-ankle pulse wave velocity (baPWV) is a non-invasive measurement, which is widely used as a surrogate marker of arterial stiffness. However, there is little evidence to show an association between NLR and baPWV in patients with peritoneal dialysis. The aim of this cross-section study was to investigate the relationship between NLR and arterial stiffness measured by baPWV in patients with peritoneal dialysis.Entities:
Keywords: Arterial stiffness; Brachial-ankle pulse wave velocity; Inflammation; Neutrophil-lymphocyte ratio; Peritoneal dialysis
Mesh:
Substances:
Year: 2016 PMID: 27881094 PMCID: PMC5122148 DOI: 10.1186/s12882-016-0394-4
Source DB: PubMed Journal: BMC Nephrol ISSN: 1471-2369 Impact factor: 2.388
Fig 1.Patient selection scheme
Baseline demographic and clinical characteristics of PD patients stratified by average baPWV level
| Variables | PWV | |||
|---|---|---|---|---|
| Low | High | T/u/ |
| |
| Age (year) | 48.60 ± 14.20 | 63.60 ± 12.65 | −5.49 | <0.01* |
| Gender (male, %) | 30(51.72) | 30(69.76) | 3.33 | 0.06 |
| Body mass index (kg/m2) | 21.16 ± 3.03 | 20.81 ± 2.83 | 0.59 | 0.55 |
| Peritoneal dialysis duration (months) | −0.05 | 0.95 | ||
| Median | 16.00 | 16.00 | ||
| Interquartile range | 4.75,45.00 | 7.00,46.00 | ||
| Diabetes (%) | 6(10.34) | 13(30.23) | 6.39 | 0.01* |
| Etiology of ESRD | 5.59 | 0.06 | ||
| Chronic glomerular nephritis (%) | 44(75.86) | 23(53.48) | ||
| Diabetic kidney disease (%) | 5(5.17) | 8(18.60) | ||
| Others(%) | 9(15.51) | 12(27.90) | ||
| current smoking status(%) | 5(8.62) | 6(13.95) | 0.72 | 0.39 |
| cardiovascular disease history(%) | 3(5.17) | 6(13.95) | 2.34 | 0.12 |
| MAP (mmHg) | 105.17 ± 17.69 | 110.93 ± 17.24 | −1.63 | 0.10 |
| Net UF (ml/day) | −1.02 | 0.30 | ||
| Median | 212.50 | 270.00 | ||
| Interquartile range | −50.00,712.50 | 70.00,720 | ||
| Urine output (ml/day) | −1.32 | 0.18 | ||
| Median | 600.00 | 500.00 | ||
| Interquartile range | 200.00,1325.00 | 20.00,1000.00 | ||
| Hemoglobin (g/L) | 104.17 ± 24.25 | 97.12 ± 18.20 | 1.66 | 0.10 |
| Albumin (g/L) | 36.18 ± 4.84 | 31.09 ± 5.70 | 4.83 | <0.01* |
| Total cholesterol (mmol/L) | 5.18 ± 1.21 | 4.64 ± 1.26 | 2.18 | 0.03* |
| Triglycerides (mmol/L) | 1.78 ± 0.95 | 1.59 ± 1.02 | 0.96 | 0.33 |
| Calcium (mmol/L) | 2.10 ± 0.24 | 2.01 ± 0.23 | 1.80 | 0.07 |
| Phosphorus (mmol/L) | 1.60 ± 0.37 | 1.37 ± 0.49 | 2.64 | 0.01* |
| Intact parathyroid hormone (pg/ml) | 434.62 ± 328.77 | 298.26 ± 240.22 | 2.30 | 0.02* |
| rGFR (ml/min/1.73 m2) | 5.67 ± 2.68 | 6.29 ± 2.96 | −1.09 | 0.27 |
| Kt/V | 2.11 ± 0.46 | 1.95 ± 0.42 | 1.71 | 0.09 |
| hsCRP(mg/dl) | −2.90 | <0.01* | ||
| Median | 1.19 | 4.68 | ||
| Interquartile range | 0.61,3.53 | 0.66,12.04 | ||
| WBC (*10^3/mm3) | 6.47 ± 1.71 | 6.42 ± 2.11 | 0.13 | 0.89 |
| Neutrophil (*10^3/mm3) | 4.32 ± 1.35 | 4.41 ± 1.71 | −0.30 | 0.76 |
| Lymphocyte(*10^3/mm3) | 1.45 ± 0.43 | 1.24 ± 0.42 | 2.45 | 0.01* |
| NLR | 3.17 ± 1.20 | 3.89 ± 1.92 | −2.15 | 0.03* |
| baPWV(cm/s) | 1506.21 ± 188.69 | 2284.45 ± 508.79 | −9.55 | <0.01* |
MAP mean arterial pressure, UF ultrafiltation, GFR glomerular filtration rate, hsCRP high-sensitive C-reactive protein, WBC white blood count, baPWV brachial-ankle pulse wave velocity, NLR neutrophil-lymphocyte ratio;*p < 0.05
Correlation analysis for variables and baPWV
| Variables |
|
|
|---|---|---|
| Age (years) | 0.47 | <0.01* |
| Body mass index (kg/m2) | −0.11 | 0.25 |
| Peritoneal dialysis duration (months) | −0.01 | 0.84 |
| Diabetes | 0.25 | 0.01* |
| current smoking status | 0.23 | 0.01* |
| atherosclerotic vascular disease history | 0.24 | 0.01* |
| MAP (mmHg) | 0.17 | 0.08 |
| Net UF (ml/day) | 0.15 | 0.13 |
| Urine output (ml/day) | 0.15 | 0.11 |
| Hemoglobin (g/L) | −0.15 | 0.12 |
| Albumin (g/L) | −0.32 | <0.01* |
| Total cholesterol (mmol/L) | −0.12 | 0.22 |
| Triglycerides (mmol/L) | −0.09 | 0.34 |
| Calcium (mmol/L) | −0.03 | 0.70 |
| Phosphorus (mmol/L) | −0.28 | <0.01* |
| Intact parathyroid hormone (pg/ml) | −0.25 | 0.01* |
| rGFR (ml/min/1.73 m2) | 0.14 | 0.13 |
| Kt/V | −0.15 | 0.12 |
| hsCRP(mg/dl) | 0.25 | 0.01* |
| WBC (*10^3/mm3) | 0.16 | 0.09 |
| Neutrophil (*10^3/mm3) | 0.24 | 0.01* |
| Lymphocyte(*10^3/mm3) | −0.23 | 0.01* |
| NLR | 0.43 | <0.01* |
MAP mean arterial pressure, UF ultrafiltation, GFR glomerular filtration rate, hsCRP high-sensitive C-reactive protein, WBC white blood count, baPWV brachial-ankle pulse wave velocity, NLR neutrophil-lymphocyte ratio;*p < 0.05
Univariate and multivariate associates of baPWV in patients with peritoneal dialysis
| Variables | baPWV | |||||
|---|---|---|---|---|---|---|
| Univariable | Multivariate | |||||
| β coefficient | t |
| β coefficient | t |
| |
| Age (year) | 0.47 | 5.38 | <0.01* | 0.25 | 2.61 | <0.01* |
| Body mass index (kg/m2) | −0.11 | −1.14 | 0.26 | -- | -- | -- |
| Diabetes (%) | 0.23 | 2.44 | 0.01* | 0.04 | 0.53 | 0.59 |
| current smoking status (%) | 0.25 | 2.55 | 0.01* | −0.18 | −1.00 | 0.31 |
| atherosclerotic vascular disease history (%) | 0.28 | 2.99 | <0.01* | 0.32 | 1.75 | 0.08 |
| MAP (mmHg) | −0.17 | 1.72 | 0.08 | -- | -- | -- |
| Albumin (g/L) | −0.31 | −3.34 | <0.01* | −0.17 | −1.99 | 0.04* |
| Calcium (mmol/L) | −0.03 | −0.37 | 0.70 | -- | -- | -- |
| Phosphorus (mmol/L) | −0.28 | −2.98 | <0.01* | −0.12 | −0.14 | 0.16 |
| iPTH (pg/ml) | −0.25 | −2.62 | 0.01* | −0.43 | −0.49 | 0.66 |
| rGFR (ml/min/1.73 m2) | 0.15 | 1.49 | 0.13 | -- | -- | -- |
| Kt/V | −0.15 | −1.57 | 0.12 | -- | -- | -- |
| hsCRP(mg/dl) | 0.19 | 1.96 | 0.05 | -- | -- | -- |
| NLR | 0.43 | 4.74 | <0.01* | 0.33 | 3.91 | <0.01* |
MAP mean arterial pressure, UF ultrafiltation, GFR glomerular filtration rate, hsCRP high-sensitive C-reactive protein, WBC white blood count, baPWV brachial-ankle pulse wave velocity, NLR neutrophil-lymphocyte ratio;*p < 0.05